Published in Antivir Ther on April 01, 2004
Future prospectives for the management of chronic hepatitis B. World J Gastroenterol (2007) 0.91
Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations. World J Gastroenterol (2013) 0.88
Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int (2010) 0.87
Comparison of amplicon-sequencing, pyrosequencing and real-time PCR for detection of YMDD mutants in patients with chronic hepatitis B. World J Gastroenterol (2006) 0.86
Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China. Hepatol Int (2007) 0.81
Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy. Ann Gastroenterol (2014) 0.79
Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off! Antivir Ther (2004) 0.79
Current antiviral therapy for chronic hepatitis B. J Korean Med Sci (2004) 0.79
Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. World J Gastroenterol (2011) 0.78
High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study. J Gastroenterol (2006) 0.76
Predictive factors of lamivudine treatment success in an hepatitis B virus-infected pediatric cohort: a 10-year study. Can J Gastroenterol (2012) 0.75
Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study. Indian J Med Res (2016) 0.75
Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31
Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy. Hepatology (2011) 2.93
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology (2002) 2.83
Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination. Gastroenterology (2012) 1.97
Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology (2004) 1.85
Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology (2006) 1.62
Determinants for sustained HBeAg response to lamivudine therapy. Hepatology (2003) 1.38
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study. Hepatology (2012) 1.31
Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS One (2012) 1.10
Comparison of murine cirrhosis models induced by hepatotoxin administration and common bile duct ligation. World J Gastroenterol (2005) 1.04
Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res (2012) 1.03
The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector/memory regulatory T cells. J Immunol (2012) 1.03
Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J Clin Microbiol (2002) 1.02
The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther (2008) 1.02
Network analysis and proteomic identification of vimentin as a key regulator associated with invasion and metastasis in human hepatocellular carcinoma cells. J Proteomics (2012) 0.95
Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int (2007) 0.94
Thyroid hormone promotes cell invasion through activation of furin expression in human hepatoma cell lines. Endocrinology (2008) 0.93
Overexpression of cyclin-dependent kinase-associated protein phosphatase enhances cell proliferation in renal cancer cells. Urol Oncol (2011) 0.92
Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis. BMC Genomics (2008) 0.91
Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma. Cancer Res (2008) 0.91
Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol (2002) 0.90
Furin overexpression suppresses tumor growth and predicts a better postoperative disease-free survival in hepatocellular carcinoma. PLoS One (2012) 0.88
Expression of the HCRP1 mRNA in HCC as an independent predictor of disease-free survival after surgical resection. Hepatol Res (2009) 0.88
Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J Hepatol (2005) 0.88
Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. Cancer Res (2003) 0.88
Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity. J Immunol (2009) 0.88
Interaction of hepatitis C virus F protein with prefoldin 2 perturbs tubulin cytoskeleton organization. Biochem Biophys Res Commun (2006) 0.87
Identification of a two-layer regulatory network of proliferation-related microRNAs in hepatoma cells. Nucleic Acids Res (2012) 0.87
Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antivir Ther (2009) 0.86
GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC. Pharmacogenomics (2011) 0.86
Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells. Hepatology (2012) 0.85
Inhibition of hepatitis C virus replication by arsenic trioxide. Antimicrob Agents Chemother (2004) 0.85
293 cells over-expressing human ADI1 and CD81 are permissive for serum-derived hepatitis C virus infection. J Med Virol (2009) 0.85
Identification of a novel actin isoform in hepatocellular carcinoma. Hepatol Res (2006) 0.84
Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation. BMC Med Genomics (2009) 0.84
Thyroid hormone enhanced human hepatoma cell motility involves brain-specific serine protease 4 activation via ERK signaling. Mol Cancer (2014) 0.83
Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders. J Gastroenterol Hepatol (2015) 0.83
Acute expression of hepatitis C core protein in adult mouse liver: Mitochondrial stress and apoptosis. Scand J Gastroenterol (2008) 0.83
Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study. Scand J Gastroenterol (2014) 0.83
New enzyme-linked immunosorbent assay for detection of antibodies against hepatitis delta virus using a hepatitis delta antigen derived from a Taiwanese clone and comparison to the Abbott radioimmunoassay. Clin Vaccine Immunol (2012) 0.83
The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer Network. Medicine (Baltimore) (2016) 0.83
Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: the influence of viral characteristics on clinical outcome. Ann Surg Oncol (2013) 0.82
SLC25A13 gene mutations in Taiwanese patients with non-viral hepatocellular carcinoma. Mol Genet Metab (2011) 0.82
Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy. J Antimicrob Chemother (2011) 0.82
HURP expression-assisted risk scores identify prognosis distinguishable subgroups in early stage liver cancer. PLoS One (2011) 0.82
Topological and evolutional relationships between HCV core protein and hepatic lipid vesicles: studies in vitro and in conditionally transgenic mice. World J Gastroenterol (2007) 0.82
Identification of potential serum markers for nasopharyngeal carcinoma from a xenografted mouse model using Cy-dye labeling combined with three-dimensional fractionation. Proteomics (2008) 0.82
One single nucleotide difference alters the differential expression of spliced RNAs between HBV genotypes A and D. Virus Res (2013) 0.81
Thyroid hormone receptor-mediated regulation of the methionine adenosyltransferase 1 gene is associated with cell invasion in hepatoma cell lines. Cell Mol Life Sci (2010) 0.80
Sexual Dimorphic Metabolic Alterations in Hepatitis C Virus-infected Patients: A Community-Based Study in a Hepatitis B/Hepatitis C Virus Hyperendemic Area. Medicine (Baltimore) (2016) 0.80
Cell cycle perturbation in the hepatocytes of HCV core transgenic mice following common bile duct ligation is associated with enhanced p21 expression. J Med Virol (2009) 0.80
Hydrodynamics-based transfection of the combination of betacellulin and neurogenic differentiation 1 DNA ameliorates hyperglycemia in mice with streptozotocin-induced diabetes. Diabetes Technol Ther (2011) 0.79
Overexpression of kappa-actin alters growth properties of hepatoma cells and predicts poor postoperative prognosis. Anticancer Res (2011) 0.79
HCV core-induced nonobese hepatic steatosis is associated with hypoadiponectinemia and is ameliorated by adiponectin administration. Obesity (Silver Spring) (2012) 0.79
Occult and Overt HBV Co-Infections Independently Predict Postoperative Prognosis in HCV-Associated Hepatocellular Carcinoma. PLoS One (2013) 0.78
Large fragment pre-S deletion and high viral load independently predict hepatitis B relapse after liver transplantation. PLoS One (2012) 0.78
Eliminating hepatitis B virus through neonatal vaccination: can we make it? J Hepatol (2012) 0.78
Reticulon 3 interacts with NS4B of the hepatitis C virus and negatively regulates viral replication by disrupting NS4B self-interaction. Cell Microbiol (2014) 0.78
A gene expression restriction network mediated by sense and antisense Alu sequences located on protein-coding messenger RNAs. BMC Genomics (2013) 0.78
Gene gun bombardment with DNA-coated gold particles is a potential alternative to hydrodynamics-based transfection for delivering genes into superficial hepatocytes. Hum Gene Ther (2008) 0.77
Emergence of mutation clusters in the HCV genome during sequential viral passages in Sip-L expressing cells. J Virol Methods (2005) 0.77
Regulation of AKR1B1 by thyroid hormone and its receptors. Mol Cell Endocrinol (2009) 0.77
Inhibition of hepatitis C virus replication by antimonial compounds. Antimicrob Agents Chemother (2005) 0.77
Sustained eradication of hepatitis C virus by low-dose long-term interferon therapy in a renal transplant recipient with dual infection with hepatitis B and C viruses: a case report. J Med Case Rep (2011) 0.76
Hydrodynamics-based transfection of pancreatic duodenal homeobox 1 DNA improves hyperglycemia and is associated with limited complications in diabetic mice. Endocr J (2009) 0.76
Infection with hepatitis B virus carrying novel pre-S/S gene mutations in female siblings vaccinated at birth: two case reports. J Med Case Rep (2010) 0.76
On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study. BMC Res Notes (2013) 0.76
An occult hepatitis B-derived hepatoma cell line carrying persistent nuclear viral DNA and permissive for exogenous hepatitis B virus infection. PLoS One (2013) 0.76
Cyclin-dependent kinase-associated protein phosphatase is overexpressed in alcohol-related hepatocellular carcinoma and influences xenograft tumor growth. Oncol Rep (2012) 0.76
Evaluation of serum matrix metalloproteinase (MMP)-9 to MMP-2 ratio as a biomarker in hepatocellular carcinoma. Hepatogastroenterology (2010) 0.76
Quantitative assessment of serum NV-F virus DNA concentrations in samples from patients coinfected with hepatitis B or C virus. J Clin Microbiol (2006) 0.75
GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy. Medicine (Baltimore) (2016) 0.75
Peritumoral small ephrinA5 isoform level predicts the postoperative survival in hepatocellular carcinoma. PLoS One (2012) 0.75
A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse. J Interferon Cytokine Res (2013) 0.75
Hepatitis B viremia in completely immunized individuals negative for anti-hepatitis B core antibody. Medicine (Baltimore) (2016) 0.75
Development of a non-invasive fibrosis test for chronic hepatitis B patients and comparison with other unpatented scores. BMC Res Notes (2013) 0.75
World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015. J Clin Gastroenterol (2016) 0.75
Primary biliary cirrhosis in antimitochondrial antibody-negative patients: Chang Gung Memorial Hospital experience. Chang Gung Med J (2003) 0.75
Is the NV-F agent a novel hepatitis virus? Future Microbiol (2009) 0.75
The various impacts of the hepatitis C virus core protein upon hepatic oxidative stress after common bile duct ligation and partial hepatectomy. Redox Rep (2008) 0.75
Dense packing of portal lymphocytes predicts favorable treatment outcome in hepatitis C. Hepatogastroenterology (2008) 0.75
Phenotypic and Genotypic Shifts in Hepatitis B Virus in Treatment-Naive Patients, Taiwan, 2008-2012. Emerg Infect Dis (2017) 0.75
Detection of hepatitis D virus RNA carrying large fragment deletions in patients with severe hepatitis B/D receiving oral antiviral therapy. J Med Virol (2015) 0.75
Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in chronic hepatitis B patients. Biomed J (2015) 0.75